Previous 10 | Next 10 |
Clene (CLNN) posted results from a mid-stage trial, which showed that the company's treatment CNM-Au8 may have the potential for neuro-repair in amyotrophic lateral sclerosis ((ALS)) patients.The Phase 2 RESCUE-ALS trial is evaluating the efficacy, safety, pharmacokinetics, and phar...
Preliminary blinded efficacy data suggest CNM-Au8 may have the potential for neuro-repair in amyotrophic lateral sclerosis (ALS) patients Patients demonstrated improvement from baseline, as compared to the expected continuous decline seen in published data from prior observation...
Clene (CLNN): Q1 GAAP EPS of -$0.66 misses by $0.56.Revenue of $0.21M (+200.0% Y/Y) beats by $0.13M.Press Release For further details see: Clene EPS misses by $0.56, beats on revenue
Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients Awarded Michael J. Fox Foundation (MJFF) grant to accelerate development of CNM-Au8 as a t...
Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharmaceuticals (PHIO) +19%.Core...
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...
Adverum Bio cut to market perform at SVB LeerinkAdverum Biotechnologies (ADVM) has gained ~3.8% in the premarket despite a downgrade by SVB Leerink to market perform from outperform. The price target of $5.00 per share implies ~28.2% upside to the last close.The cancella...
Clene (CLNN) and and its wholly owned subsidiary Clene Nanomedicine announce the U.S. Patent and Trademark Office has issued "Notices of Allowance" for two patent applications covering device and process claims for its platform technology and advanced stage clean-surfaced nanoc...
SALT LAKE CITY, April 30, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegen...
Clene (CLNN): FY GAAP EPS of -$1.10 misses by $0.65.Revenue of $0.21M beats by $0.01M.Press Release For further details see: Clene EPS misses by $0.65, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...